Giants of Cancer Care® Program Inductees

LYMPHOID NEOPLASMS

Emil J. Freireich, MD, DSc

The University of Texas MD Anderson Cancer Center

Emil J. Freireich, MD, is the Ruth Harriet Ainsworth Chair in the Department of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center.
Collaborated with James Holland, MD, and Emil Frei III, MD, to develop combination chemotherapy and organize the first cooperative group
Developed the first “curative therapy” for metastatic cancer in childhood acute lymphoblastic leukemia: POMP—prednisone, oncovin, methotrexate, purinethol (6-MP)
First to perform leukocyte transfusion and to demonstrate engrafting of peripheral blood stem cells, providing allogeneic bone marrow grafts
Developed allogeneic platelet transfusion and treatment strategies for infectious complications
Patented the first continuous-flow blood cell separator, which is used in most pheresis centers
Continues to work in the Department of Leukemia, where he cares for patients with leukemia and supervises research protocols for treatment of this disease
In his joint appointment with the Department of Laboratory Medicine, collaborates on an important transfusion study
Obtained one of the first formal training program grants in medical oncology at MD Anderson, and serves on the Division of Cancer Medicine Committee for Medical Oncology Fellow Training

Home

)

SUPPORTED BY